Drug Profile
Research programme: antibody therapeutics - Teva
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Innate Immune
- Developer Cephalon
- Class Antibodies
- Mechanism of Action Natural killer cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Asthma in Australia
- 14 Oct 2011 Cephalon has been acquired by Teva Pharmaceutical Industries
- 16 Mar 2010 Early research in Asthma in Australia (unspecified route)